GenapSys is a biotech company that has developed a novel DNA sequencing technology and detection system for applied genomic testing and medical sequencing.
GenapSys is enabling a new era of genomic testing and a new paradigm of how we engage the molecular world.
GenapSys was founded in 2010 by Hesaam Esfandyarpour. The company is headquartered in Redwood City, California.
GenapSys' novel electrical-based platform capable of accurately detecting single base incorporations. The semiconductor chip-based detection modality allows the system to be compact, scalable, and affordable.
The GenapSys platform has been successfully demonstrated in a range of applications that include targeted sequencing to elucidate both germline and somatic mutations, as well as sequencing a range of small genomes.
GenapSys is also developing a cost-disruptive, easy-to-use DNA sequencing device based on simple, label-free proprietary GENIUS™ technology, which delivers significant improvement in cost and speed. These innovations will enable a new era of discovery through the widespread integration of genomic and other molecular data for research and applications.
GenapSys is backed by Foresite Capital, IPV Capital, Stanford StartX Fund and others. The company raised $75M in a Debt financing on Feb 06, 2020. This new round brings GenapSys' total funding to $241M to date.